TRAP1 and neoplasm: In summary, our data suggest that OXPHOS is enhanced in CAFs in the TME in response to TRAP1 deficiency in mitochondria which is associated with changes in basal respiration, ATP production, maximal respiration and SRC, and Overexpression of TRAP1 in CAFs promotes tumor progression in vivo; these changes contribute to the progression of OSCC, making OXPHOS inhibition an attractive therapeutic strategy for targeting both tumor cells and the surrounding stroma.